The effects of insulin sensitizers on the cardiovascular risk factors in women with polycystic ovary syndrome (Q37402281)

20 August 2017

1 reference

title

The effects of insulin sensitizers on the cardiovascular risk factors in women with polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

20 August 2017

main subject

1 reference

1 reference

1 reference

Evanthia Diamanti-Kandarakis

series ordinal

2

object named as

Diamanti-Kandarakis E

1 reference

20 August 2017

Kassi E

1

1 reference

20 August 2017

publication date

1 December 2008

1 reference

Journal of Endocrinological Investigation

20 August 2017

published in

1 reference

20 August 2017

volume

31

1 reference

20 August 2017

issue

12

1 reference

20 August 2017

page(s)

1124-1131

1 reference

The prevalence and features of the polycystic ovary syndrome in an unselected population

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Molecular mechanisms of insulin resistance in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Predictors of endothelial dysfunction in young women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Pathophysiology and types of dyslipidemia in PCOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Indices of low-grade inflammation in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

The plasminogen activator system in young and lean women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Accumulation of dietary glycotoxins in the reproductive system of normal female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Plasma adiponectin levels and risk of myocardial infarction in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Serum adiponectin levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Adiponectin: A novel adipokine linking adipocytes and vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Early metabolic derangements in daughters of women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Mortality of women with polycystic ovary syndrome at long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

The new adipose tissue and adipocytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Metformin administration improves endothelial function in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

The polycystic ovary syndrome per se is not associated with increased chronic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute spons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345663

Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome

21 January 2018

1 reference

12 December 2020

[Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy]

1 reference

12 December 2020

Interactive stimulation by luteinizing hormone and insulin of the steroidogenic acute regulatory (StAR) protein and 17alpha-hydroxylase/17,20-lyase (CYP17) genes in porcine theca cells

1 reference

12 December 2020

A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

1 reference

12 December 2020

Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity

1 reference

12 December 2020

Sites of inhibition of steroidogenesis by activation of protein kinase-C in swine ovarian (granulosa) cells

1 reference

12 December 2020

Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis

1 reference

12 December 2020

Concerted transcriptional activation of the low density lipoprotein receptor gene by insulin and luteinizing hormone in cultured porcine granulosa-luteal cells: possible convergence of protein kinase a, phosphatidylinositol 3-kinase, and mitogen-act

1 reference

12 December 2020

Increased plasma visfatin concentrations in women with polycystic ovary syndrome

1 reference

12 December 2020

Inflammatory and endothelial markers in women with polycystic ovary syndrome

1 reference

12 December 2020

Androgen effect on insulin action and glucose metabolism

1 reference

12 December 2020

Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome1

1 reference

12 December 2020

The effect of rosiglitazone on plasma adiponectin and resistin levels in obese PCO woman--preliminary report

1 reference

12 December 2020

The effect of insulin and insulin-like growth factors on the expression of steroidogenic enzymes in a human ovarian thecal-like tumor cell model

1 reference

12 December 2020

Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study

1 reference

12 December 2020

Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women

1 reference

12 December 2020

The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile

1 reference

12 December 2020

Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women

1 reference

12 December 2020

Metformin and glitazones: do they really help PCOS patients?

1 reference

12 December 2020

Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome

1 reference

12 December 2020

The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome

1 reference

12 December 2020

The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome

1 reference

12 December 2020

New perspectives in polycystic ovary syndrome

1 reference

12 December 2020

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

12 December 2020

Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects

1 reference

12 December 2020

Polycystic ovarian syndrome: the commonest cause of hyperandrogenemia in women as a risk factor for metabolic syndrome

1 reference

12 December 2020

The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome--a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy

1 reference

12 December 2020

Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03345663

1 reference

20 August 2017

1 reference